The global pharmaceutical industry is entering a new phase of restructuring. Since 2025, multinational drugmakers have begun recalibrating their workforce strategies as they redirect investments toward automation, biologics, and next-generation therapies.
Unlike previous cycles marked by large-scale, highly visible layoffs, many organisations are now adopting more measured approaches. Voluntary separation schemes (VSS), internal redeployments, and gradual restructuring programmes are increasingly being used to optimise workforce structures while maintaining operational continuity.
For globally integrated markets such as Malaysia, these shifts may not always be immediately visible—but their impact on the local talent landscape is real and evolving.
Global Pharma Restructuring: Key Trends and Examples
Across the pharmaceutical sector, organisations are reassessing cost structures while accelerating investments in innovation and advanced manufacturing capabilities.
Several major players have already initiated restructuring efforts:
Novo Nordisk has undertaken workforce adjustments amid intensifying competition in the global obesity drug market
GSK has streamlined parts of its R&D organisation to support broader efficiency and technology initiatives
Pfizer continues to optimise its global cost base following post-pandemic demand normalisation
Novartis is restructuring manufacturing operations while increasing investment in advanced therapies and production technologies
In most cases, these changes are being implemented through phased or voluntary programmes rather than abrupt workforce reductions. This reflects a broader shift toward controlled, strategic restructuring rather than reactive cost-cutting.
Why Pharmaceutical Companies Are Restructuring
Three structural forces are driving this transformation across the industry.
Patent Expirations - The loss of exclusivity on blockbuster drugs continues to pressure revenue streams, forcing companies to rebalance portfolios and reduce legacy cost structures.
Cost and Competitive Pressures - Therapeutic areas such as obesity, oncology, and specialty care are becoming increasingly competitive. Companies are under pressure to improve efficiency while sustaining high levels of R&D investment. For example, competition between Novo Nordisk and Eli Lilly in the obesity segment has intensified the need for cost discipline and operational focus.
Shift Toward Advanced Manufacturing- The transition toward biologics, RNA-based therapies, and precision medicine is reshaping how pharmaceuticals are developed and produced. Companies such as Novartis are investing heavily in next-generation manufacturing platforms, automation, and digital integration.
This shift is not just technological—it is fundamentally changing workforce requirements across the industry.
What This Means for Malaysia’s Life Sciences Sector
Malaysia remains a key node within the global pharmaceutical value chain, supporting manufacturing, regional commercial operations, and shared services.
Key industry hubs include:
Selangor
Penang
Johor
While restructuring decisions are typically driven at global headquarters, their effects often cascade into regional operations. In Malaysia, this may translate into more cautious hiring, internal restructuring, or selective workforce adjustments.
These changes are rarely headline-driven but can gradually influence the availability, mobility, and expectations of talent within the market.
Talent Implications: A Shifting Workforce Landscape
As global organisations realign, the Malaysian talent market may see an increase in experienced professionals entering the workforce—particularly at the mid-to-senior level.
Roles most likely to be impacted include:
Regulatory Affairs Managers
Quality Assurance and Compliance Specialists
Medical Affairs Leaders
Pharmaceutical Sales Directors
Manufacturing and Operations Managers
For employers, this creates a strategic opportunity to access high-quality talent with multinational experience. However, it also introduces greater competition among candidates for a relatively concentrated pool of roles within the life sciences sector.
Where New Opportunities Are Emerging
Despite restructuring activity, the pharmaceutical industry continues to invest in high-growth and innovation-driven areas.
Key opportunity segments include:
1. Advanced Manufacturing - Automation and smart manufacturing systems are becoming central to pharmaceutical production.
2. Biologics and RNA-Based Therapies - The rise of mRNA and siRNA technologies is driving demand for specialised scientific and technical expertise.
3. Digital Health and Data Capabilities- AI-driven research, clinical data analytics, and digital health platforms are reshaping how pharmaceutical companies operate and deliver value.
Organisations investing in these areas—such as Novartis and Pfizer—are increasingly prioritising talent with cross-functional and technology-driven skill sets.
Supporting Workforce Transitions Through Outplacement
As workforce restructuring becomes more strategic and continuous, organisations are placing greater emphasis on managing employee transitions.
Outplacement and career transition programmes are emerging as critical tools to support affected employees while protecting employer brand and organisational reputation. Structured support—ranging from career coaching to job placement assistance—enables companies to manage change more responsibly and maintain long-term talent relationships.
For industries such as pharmaceuticals, where specialised talent is highly interconnected, this approach is becoming less of an option and more of a standard expectation.
Outlook for 2026
Restructuring activity across the pharmaceutical sector is expected to continue into 2026 as companies balance cost optimisation with long-term innovation strategies.
For Malaysia, the long-term outlook remains positive. The country’s position as a regional hub for pharmaceutical manufacturing and operations continues to strengthen, supported by infrastructure, talent availability, and strategic location.
However, the nature of employment within the sector is evolving. Workforce demand is shifting toward specialised, technology-driven roles, and both employers and professionals will need to adapt accordingly.
In this environment, agility will define success in the next phase of the pharmaceutical talent market.
Explore hiring intentions, talent availability, salary expectations, and emerging skills shaping Malaysia's pharmaceutical industry in our latest Malaysia Talent Market Report 2026. Download the Talent Report to support smarter workforce planning and stay ahead of industry shifts > https://bit.ly/4sK6Lru
Support your employees through change with Monroe Consulting Group's outplacement solutions. Get in touch with us today.
